Revenue Performance - Total revenues for Q3 2025 were $5,143 million, representing a 6% increase year-over-year, with organic growth of 4%[183] - For the nine months ended September 30, 2025, total revenues reached $14,927 million, a 4% increase year-over-year, with organic growth of 3%[184] - The U.S. and Canada region generated $2,358 million in Q3 2025, a 5% increase from the previous year[182] - The EMEA region saw a 10% revenue increase to $1,360 million in Q3 2025[182] - Total revenues for the three months ended September 30, 2025, were $5,143 million, a 6% increase compared to $4,863 million in the same period of 2024[204] Segment Performance - Product sales increased by 5% or $174 million, driven by strong growth in Pharmaceutical Diagnostics (PDx), Imaging, and Advanced Visualization Solutions (AVS)[183] - Service sales grew by 6% or $107 million, primarily due to growth in new and existing customer contractual agreements[183] - Segment revenues for Imaging were $2,349 million in Q3 2025, a 5% increase from Q3 2024[181] - PDx segment revenues increased by 20% to $749 million in Q3 2025, with a 10% organic growth[181] - Imaging segment revenues were $2,349 million, growing 5% or $120 million, driven by growth in the EMEA and USCAN regions[185] - AVS segment revenues were $1,301 million, growing 7% or $84 million, with strength in the U.S. market[185] - PDx segment revenues were $749 million, growing 20% or $124 million, driven by the acquisition of Nihon Medi-Physics Co., Ltd. and an increase in Organic revenue, which grew 10%[185] Income and Profitability - The company reported a net income attributable to GE HealthCare of $446 million for Q3 2025, compared to $470 million in Q3 2024[180] - Operating income for Q3 2025 was $653 million, a decrease from $676 million in Q3 2024[180] - Net income attributable to GE HealthCare for the nine months ended September 30, 2025, was $1,495 million, an increase of 18% compared to the previous year[186] - Adjusted EBIT for the three months ended September 30, 2025, was $761 million, a decrease of 4% compared to the previous year[188] - Gross profit decreased by $36 million or 300 basis points as a percent of Total revenues due to increased costs of products and services sold[190] Expenses and Taxation - Total operating expenses decreased by $13 million, with a decrease in R&D investments of $25 million[190] - Provision for income taxes increased by $11 million primarily due to U.S. and foreign tax law changes[190] - Adjusted tax expense for the nine months ended September 30, 2025, was $(377) million, a decrease from $(401) million in 2024, with an adjusted effective tax rate of 20.2% compared to 21.9% in 2024[214] Cash Flow and Capital Structure - Free cash flow for the nine months ended September 30, 2025, was $589 million, down 21% from $743 million in 2024, with cash from operating activities decreasing by 10% to $937 million[217][226] - Cash and cash equivalents as of September 30, 2025, totaled $4,027 million, with access to revolving credit facilities of $3,500 million[218] - Total debt increased to $10,282 million as of September 30, 2025, from $8,951 million at the end of 2024, primarily due to new senior unsecured notes issued[229] - Cash generated from financing activities for the nine months ended September 30, 2025, was $910 million, including $1,487 million from new senior unsecured notes issuance[224] - Operating activities generated cash of $937 million for the nine months ended September 30, 2025, with net income of $1,552 million[220] Capital Expenditures and Compliance - Capital expenditures for the nine months ended September 30, 2025, were $348 million, primarily for manufacturing capacity expansion and new product introductions[227] - The company maintained compliance with credit facility covenants as of September 30, 2025, including the maximum consolidated net leverage ratio[230] - Credit ratings as of October 22, 2025, were Baa2 from Moody's, BBB from S&P, and BBB from Fitch, all with a stable outlook[233]

Financial Performance - Revenue for Q3 2025 was $5.1 billion, representing a 6% increase year-over-year, with organic revenue growth of 4% driven by EMEA and the U.S.[7] - Net income attributable to GE HealthCare was $446 million, down from $470 million in the prior year, resulting in a net income margin of 8.7%[7] - Diluted earnings per share (EPS) were $0.98, a decrease of $0.05 from the previous year, while adjusted EPS was $1.07, down $0.06 year-over-year[7] - Adjusted net income for Q3 2025 was $490 million, a decrease of 6% from $521 million in Q3 2024; for the nine months ended September 30, 2025, it increased by 3% to $1,441 million from $1,393 million in 2024[33] - The company reported a 18% increase in net income attributable to GE HealthCare for the nine months ended September 30, 2025, reaching $1,495 million compared to $1,272 million in 2024[33] Cash Flow and Investments - Cash flow from operating activities was $593 million, a decrease of $149 million year-over-year, and free cash flow was $483 million, down $168 million year-over-year[7] - Cash from operating activities for continuing operations decreased to $937 million in 2025 from $1,042 million in 2024, reflecting a decline of 10%[18] - Cash flows from investing activities for continuing operations totaled $(778) million in 2025, compared to $(674) million in 2024, indicating increased investment activity[18] - The company issued new debt amounting to $1,494 million in 2025, up from $994 million in 2024, reflecting a strategy to enhance liquidity[18] - Cash, cash equivalents, and restricted cash at the end of the period increased to $4,030 million in 2025 from $3,572 million in 2024[18] Revenue Segments - Imaging segment revenues were $2.349 billion, with a year-over-year growth of 5%, while Pharmaceutical Diagnostics saw a 20% increase in revenues[8] - Organic orders growth was 6%, with growth across all segments, and total company book-to-bill ratio was 1.06 times[6] - Total revenues for the nine months ended September 30, 2025, reached $14,927 million, a 4% increase from $14,353 million in 2024[26] - Organic revenue for the nine months ended September 30, 2025, was $14,792 million, representing a 3% growth compared to $14,349 million in 2024[26] - The company reported a 20% increase in PDx revenues for the three months ended September 30, 2025, reaching $749 million compared to $625 million in 2024[26] Guidance and Future Outlook - The company raised the lower end of its full-year 2025 adjusted EPS guidance range, now expecting adjusted EPS between $4.51 and $4.63[10] - Tariff impacts are estimated to affect adjusted EBIT by approximately $265 million and adjusted EPS by $0.45 for the full year[12] Operational Highlights - The company launched several new products, including CareIntellect for Perinatal and the AI-supported solution for radiation therapy workflow[11] - GE HealthCare announced the intent to acquire icometrix to enhance its neurology portfolio with brain MRI assessment solutions[11] - Non-operating benefit costs for Q3 2025 were $(75) million, compared to $(102) million in Q3 2024[33] - Restructuring costs for Q3 2025 were $31 million, up from $22 million in Q3 2024; for the nine months ended September 30, 2025, restructuring costs totaled $71 million, down from $90 million in 2024[33] Company Recognition and Contact Information - GE HealthCare is recognized as one of the 2025 Fortune World's Most Admired Companies™[49] - Investor Relations contact is Carolynne Borders, reachable at +1-631-662-4317[49] - Media contact is Jennifer Fox, reachable at +1-414-530-3027[49] - The company encourages following its social media channels for the latest news[49] - More information can be found on the official website: https://www.gehealthcare.com[49] Tax and Effective Rates - The effective tax rate for Q3 2025 was 27.8%, compared to 25.5% in Q3 2024; the adjusted effective tax rate was 21.8% for Q3 2025, up from 18.7% in Q3 2024[37]

Constellium PRESS RELEASE October 29, 2025 Constellium Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Guidance Paris - Constellium SE (NYSE: CSTM) ("Constellium", the "Company" or the "Group") today reported results for the third quarter and the nine months ended September 30, 2025. Third quarter 2025 highlights: Nine months ended September 30, 2025 highlights: 1 During the third quarter of 2025, the Company identified and corrected certain immaterial errors affecting metal price lag and t ...

Exhibit 99.1 "Avantor's diverse portfolio, strong production capabilities, and long-standing customer relationships provide a strong foundation for sustained value creation," said Emmanuel Ligner, President and Chief Executive Officer. "To position Avantor for success in any macroeconomic environment, we are making decisive, meaningful changes aimed at improving execution, accountability and financial performance. We are taking action to evolve our go-to-market approach, sharpen our customer value propositi ...

Exhibit 99.1 NEWS RELEASE te.com TE Connectivity delivers 17% sales growth in fiscal fourth quarter with results above guidance Achieves full-year records in sales, operating margin and cash generation GALWAY, Ireland – Oct. 29, 2025 – TE Connectivity plc (NYSE: TEL) today reported results for the fiscal fourth quarter and fiscal year ended September 26, 2025. Fourth Quarter Highlights Full Year Highlights ● Net sales were a record $4.75 billion, an increase of 17% on a reported basis year over year and 11% ...

Fresh Del Monte Produce Inc. Reports Third Quarter Earnings for Fiscal 2025 Agreement to Divest Mann Packing to Enhance Margin Profile Strategic Focus Drives Gross Margin Expansion in Fresh and Value-added Products Segment Exit of Underperforming Banana Farms Supports Long-Term Productivity and Operational Resilience CORAL GABLES, FL. - October 29, 2025 - Fresh Del Monte Produce Inc. (NYSE: FDP), ("Fresh Del Monte" or the "Company") today reported financial results for the third quarter ended September 26, ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _______ Commission File No. 001-38911 CLARIVATE PLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Exhibit 99 OTIS REPORTS THIRD QUARTER 2025 RESULTS Otis delivers 6% organic Service sales growth with strong Service operating profit margin expansion, and increases the midpoint of 2025 EPS outlook Third quarter 2025 Year-to-date 2025 FARMINGTON, Conn., October 29, 2025 – Otis Worldwide Corporation (NYSE:OTIS) reported third quarter 2025 net sales of $3.7 billion with organic sales up 2% versus the prior year. GAAP earnings per share (EPS) decreased 29% to $0.95 and adjusted EPS increased 9% to $1.05. "Oti ...

Clarivate Reports Third Quarter 2025 Results — Continued acceleration of organic ACV — — Raises 2025 Revenues Outlook — — Repurchased 11.7 million ordinary shares and repaid $100 million of debt in the third quarter — London, UK -- October 29, 2025 Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2025. "The third quarter demonstrated continued improved financial and operationa ...

Exhibit 99.1 October 29, 2025 SiteOne Landscape Supply Announces Third Quarter 2025 Earnings Third Quarter 2025 Highlights (Compared to Third Quarter 2024): Post Quarter Highlights ROSWELL, Ga. — (BUSINESS WIRE) — SiteOne Landscape Supply, Inc. (the "Company" or "SiteOne") (NYSE: SITE) announced earnings for its third quarter ended September 28, 2025 ("Third Quarter 2025"). "We are pleased to report another quarter of strong operational performance, delivering double-digit year-over-year Adjusted EBITDA gro ...